OCC Stock Overview
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Orthocell Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.46 |
| 52 Week High | AU$0.46 |
| 52 Week Low | AU$0.32 |
| Beta | 1.16 |
| 11 Month Change | 19.48% |
| 3 Month Change | 24.32% |
| 1 Year Change | 29.58% |
| 33 Year Change | -8.00% |
| 5 Year Change | 17.95% |
| Change since IPO | 27.78% |
Recent News & Updates
Recent updates
Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Sep 09
It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year
Oct 25We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth
Nov 16We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate
Jul 29Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans
Mar 23We're Not Worried About Orthocell's (ASX:OCC) Cash Burn
Dec 08Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation
May 31Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth
Feb 15How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?
Dec 24Shareholder Returns
| OCC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 24.3% | -2.0% | -1.7% |
| 1Y | 29.6% | 13.2% | 10.2% |
Return vs Industry: OCC exceeded the Australian Biotechs industry which returned 13.2% over the past year.
Return vs Market: OCC exceeded the Australian Market which returned 10.2% over the past year.
Price Volatility
| OCC volatility | |
|---|---|
| OCC Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: OCC has not had significant price volatility in the past 3 months.
Volatility Over Time: OCC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Paul Anderson | orthocell.com |
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair.
Orthocell Limited Fundamentals Summary
| OCC fundamental statistics | |
|---|---|
| Market cap | AU$92.21m |
| Earnings (TTM) | -AU$7.18m |
| Revenue (TTM) | AU$5.32m |
18.1x
P/S Ratio-13.4x
P/E RatioIs OCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCC income statement (TTM) | |
|---|---|
| Revenue | AU$5.32m |
| Cost of Revenue | AU$1.63m |
| Gross Profit | AU$3.69m |
| Other Expenses | AU$10.87m |
| Earnings | -AU$7.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 69.39% |
| Net Profit Margin | -135.10% |
| Debt/Equity Ratio | 0% |
How did OCC perform over the long term?
See historical performance and comparison